Open or closed? Structural characterization of plasma-derived and recombinant human plasminogen across multiple resolution scales.
Kasiarova, L., Verma, N., Pinkas, M., Henek, T., Klumpler, T., Chovancikova, M., Reutova, H., Kasparek, P., Hlozankova, M., Damborsky, J., Novacek, J., Hernychova, L., Marek, M.(2026) Int J Biol Macromol : 154885-154885
- PubMed: 42896770 Search on PubMed
- DOI: https://doi.org/10.1016/j.ijbiomac.2026.154885
- Primary Citation Related Structures: 
32JR - PubMed Abstract: 
Plasminogen (Plg), the zymogen of the fibrinolytic protease plasmin, is a multidomain, conformationally rich protein that plays a crucial role in targeted thrombolysis for stroke and heart attack treatments. Yet, the conformational state that affects binding to Plg activators and fibrinolytic activity is rarely validated, contributing to poor reproducibility and failures in drug development. Here, we establish a structural biology workflow to characterize human Plg suspended in an aqueous solution, preserving it in a near-native state and eliminating the need for crystal growth. Two variants, cleavage-resistant Plg-RV (R561A) and catalytically inactive Plg-CAT (S741A), were expressed in mammalian cells. Both variants showed comparable global secondary structure and thermal stability (Tm ≈ 60.6 °C) and were resistant to staphylokinase-mediated activation, in contrast to commercial plasma-derived Plg. Small-angle X-ray scattering revealed substantial conformational heterogeneity, and hydrogen‑deuterium exchange mass spectrometry mapped staphylokinase-associated local structural changes. The recombinantly-produced Plg variants adopted a closed conformation, exhibiting a good fit to the closed structure determined by X-ray diffraction. Conversely, the plasma-derived Plg populated an extended, open-like state. Cryo-EM analysis of the Plg-RV variant yielded a 4.4 Å resolution map, and a rigid-body-fitted model revealed the closed-state architecture. Our findings demonstrate that rigorous structural validation of Plg is essential for future functional studies and rational development of next-generation thrombolytic agents.
- Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5, Bld. C13, 625 00, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, 656 91, Brno, Czech Republic.
Organizational Affiliation: 

